A need exists to develop safe and efficacious medications to treat major diseases such as cancer and infectious diseases. In response to this need, we synthesized a novel enaminone, which structurally belongs to the trithiocarbonate class engrafted by an enaminone group. The anticancer and antimicrobial activities were evaluated by utilizing three different types of human cancer (MDA-MB-231, LoVo, and HepG2) and a wide field of microbes (G⁺ and G⁻ bacteria, yeast, and molds). The tested compound 3 exhibited moderate growth suppression activity versus all examined human tumor cells, with values of IC₅₀ ranging from 35 to 45 µg/ml. Moreover, the antimicrobial effects of compound 3 were more profound against fungal pathogens than against bacterial pathogens (minimal inhibitory concentrations; fungi, 0.08–0.14 mg/ml; bacteria, 0.3–1.4 mg/ml). These findings lay the foundation for designing improved bioactive agents that could be utilized as anticancer and/or antimicrobial agents.

中文翻译：

---

新型烯胺酮接枝的三硫代碳酸酯的合成和生物筛选：潜在的抗癌和抗菌剂

需要开发安全有效的药物来治疗主要疾病，例如癌症和传染病。为响应这一需求，我们合成了一种新型的烯胺酮，其结构上属于烯胺酮基团接枝的三硫代碳酸酯类。（G的抗癌和抗微生物活性通过利用三种不同类型的人类癌症（MDA-MB-231，株LoVo，和HepG2）和微生物的宽视场的评价⁺和G ^-细菌，酵母和霉菌）。与所有检查的人类肿瘤细胞相比，受试化合物3表现出中等的生长抑制活性，IC ₅₀值为35至45 µg / ml。此外，化合物3的抗菌作用对真菌病原体的抵抗力要强于对细菌病原体的抵抗力（最小抑菌浓度；真菌，0.08-0.14 mg / ml；细菌，0.3-1.4 mg / ml）。这些发现为设计改进的可用作抗癌和/或抗微生物剂的生物活性剂奠定了基础。